Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results

Wednesday, May 11, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

Orexigen Therapeutics, Inc.

Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended

March 31,

2011

2010

Revenues:

Collaborative agreement

$

857

$

-

License revenue

971

22

Total revenues

1,828

22

Operating expenses:

Research and development

6,567

7,981

General and administrative

6,759

6,021

Total operating expenses

13,326

14,002

Loss from operations

(11,498)

(13,980)

Other income (expense):

Interest income

15

46

Interest expense

(120)

(145)

Total other income (expense)

(105)

(99)

Net loss

$

(11,603)

$

(14,079)

Net loss per share - basic and diluted

$

(0.24)

$

(0.30)

Shares used in computing net loss per share – basic and diluted

47,867

47,216



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store